Conducted in part by the University of Cape Town (UCT), the study looked at whether it was possible for nurses – instead of laboratory technicians – to administer the test in clinics in four countries, South Africa, Zimbabwe, Zambia and Tanzania.
Introduced in South Africa in 2011, the GeneXpert can diagnose TB as well as some forms of drug-resistant TB in just hours. Conventional TB testing, which relied on microscopes and chest x-rays, can take weeks. These methods also miss up to 60 percent of TB cases.
However, the GeneXpert is currently only largely used in South African laboratories, meaning clinics must send samples to these labs for testing and wait several days for results to come back.
“We asked a simple question, if we put this technology in the clinic and the test is performed by a minimally trained health care worker will that impact on patient drop out and what are the potential benefits of that strategy?” says study co-author. Keertan Dheda from UCT’s Department of Medicine.
Published in the 28 October online edition of the Lancet, Dheda’s study found that nurses could accurately run the GeneXpert machines with a single day’s training.
The research also found that placing GeneXperts in clinics doubled the same day diagnostic rate and also increased the number of patients starting same day treatment by 50 percent.
“What this translates into is halving patient drop out so a lot more patients returned or were put on treatment compared to those who were tested using traditional smear microscopy,” he explains.
Only half of all patients diagnosed with multidrug-resistant (MDR-TB) in South Africa receive treatment.
Expanding access to the GeneXpert, which can also diagnose MDR-TB, will help the country combat rising rates of extensively drug-resistant TB (XDR-TB), Dheda says.
“Unless we rapidly diagnose cases of MDR-TB and rapidly act to treat these patients then this problem of XDR-TB and incurable TB is going to get bigger and bigger,” warns Dheda, who suggests placing GeneXperts in clinics in drug-resistant TB hotspots around the country.
Each year, South Africa reports more cases of XDR-TB than any other country in the world. Only 16 percent of TB cases are currently tested for MDR-TB.
MDR-TB is resistant to both commonly used anti-TB drugs. XDR-TB is resistant to these drugs as well as at least half of the mostly commonly used second-line drugs. – Health-e News Service.